Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain

Mohamed A. Hamza, Paul F. White, William F. Craig, El Sayed A Ghoname, Hesham E. Ahmed, Timothy J. Proctor, Carl E. Noe, Akshay S. Vakharia, Noor Gajraj

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

OBJECTIVE - To evaluate the use of percutaneous electrical nerve stimulation (PENS) in the management of patients with painful diabetic peripheral neuropathy RESEARCH DESIGN AND METHODS - A total of 50 adult patients with type 2 diabetes and peripheral neuropathic pain of >6 months duration involving the lower extremities were randomly assigned to receive active PENS (needles with electrical stimulation at an alternating frequency of 15 and 30 Hz) and sham (needles only) treatments for 3 weeks. Each series of treatments was administered for 30 min three times a week according to a standardized protocol. After a 1-week washout period, all patients were subsequently switched to the other modality. A 10-cm visual analog scale (VAS) was used to assess pain, physical activity, and quality of sleep before each session. The changes in VAS scores and daily requirements for oral analgesic medication were determined during each 3-week treatment period. Patients completed the MOS 36-Item Short-Form Health Survey (SF-36), the Beck Depression Inventory (BDI), and the Profile of Mood States (POMS) before and after completion of each treatment modality. At the end of the crossover study, a patient preference questionnaire was used to compare the effectiveness of the two modalities. RESULTS - Compared with the pain VAS scores before active (6.2 ± 1.0) and sham (6.4 ± 0.9) treatments, pain scores after treatment were reduced to 215 ± 0.8 and 6.3 ± 1.1, respectively with active PENS treatment, the VAS activity and sleep scores were significantly improved from 5.2 ± 1.0 and 5.8 ± 1.3 to 7.9 ± 1.0 and 8.3 ± 0.7, respectively. The VAS scores for pain, activity, and sleep were unchanged from baseline values after the sham treatments. Patients' daily oral nonopioid analgesic requirements decreased by 49 and 14% after active and sham PENS treatments, respectively. The post-treatment physical and mental components of the SF-36, the BDI, and the POMS all showed a significantly greater improvement with active versus sham treatments. Active PENS treatment improved the neuropathic pain symptoms in all patients. CONCLUSIONS - PENS is a useful nonpharmacological therapeutic modality for treating diabetic neuropathic pain. In addition to decreasing extremity pain, PENS therapy improved physical activity, sense of well-being, and quality of sleep while reducing the need for oral nonopioid analgesic medication.

Original languageEnglish (US)
Pages (from-to)365-370
Number of pages6
JournalDiabetes Care
Volume23
Issue number3
StatePublished - Mar 2000

Fingerprint

Transcutaneous Electric Nerve Stimulation
Neuralgia
Analgesics
Sleep
Visual Analog Scale
Therapeutics
Non-Narcotic Analgesics
Pain Measurement
Pain
Needles
Placebos
Exercise
Depression
Electric Stimulation Therapy
Equipment and Supplies
Patient Preference
Diabetic Neuropathies
Peripheral Nervous System Diseases
Health Surveys
Cross-Over Studies

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Hamza, M. A., White, P. F., Craig, W. F., Ghoname, E. S. A., Ahmed, H. E., Proctor, T. J., ... Gajraj, N. (2000). Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain. Diabetes Care, 23(3), 365-370.

Percutaneous electrical nerve stimulation : A novel analgesic therapy for diabetic neuropathic pain. / Hamza, Mohamed A.; White, Paul F.; Craig, William F.; Ghoname, El Sayed A; Ahmed, Hesham E.; Proctor, Timothy J.; Noe, Carl E.; Vakharia, Akshay S.; Gajraj, Noor.

In: Diabetes Care, Vol. 23, No. 3, 03.2000, p. 365-370.

Research output: Contribution to journalArticle

Hamza, MA, White, PF, Craig, WF, Ghoname, ESA, Ahmed, HE, Proctor, TJ, Noe, CE, Vakharia, AS & Gajraj, N 2000, 'Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain', Diabetes Care, vol. 23, no. 3, pp. 365-370.
Hamza MA, White PF, Craig WF, Ghoname ESA, Ahmed HE, Proctor TJ et al. Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain. Diabetes Care. 2000 Mar;23(3):365-370.
Hamza, Mohamed A. ; White, Paul F. ; Craig, William F. ; Ghoname, El Sayed A ; Ahmed, Hesham E. ; Proctor, Timothy J. ; Noe, Carl E. ; Vakharia, Akshay S. ; Gajraj, Noor. / Percutaneous electrical nerve stimulation : A novel analgesic therapy for diabetic neuropathic pain. In: Diabetes Care. 2000 ; Vol. 23, No. 3. pp. 365-370.
@article{6258012259fa43fc805eb152027b192d,
title = "Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain",
abstract = "OBJECTIVE - To evaluate the use of percutaneous electrical nerve stimulation (PENS) in the management of patients with painful diabetic peripheral neuropathy RESEARCH DESIGN AND METHODS - A total of 50 adult patients with type 2 diabetes and peripheral neuropathic pain of >6 months duration involving the lower extremities were randomly assigned to receive active PENS (needles with electrical stimulation at an alternating frequency of 15 and 30 Hz) and sham (needles only) treatments for 3 weeks. Each series of treatments was administered for 30 min three times a week according to a standardized protocol. After a 1-week washout period, all patients were subsequently switched to the other modality. A 10-cm visual analog scale (VAS) was used to assess pain, physical activity, and quality of sleep before each session. The changes in VAS scores and daily requirements for oral analgesic medication were determined during each 3-week treatment period. Patients completed the MOS 36-Item Short-Form Health Survey (SF-36), the Beck Depression Inventory (BDI), and the Profile of Mood States (POMS) before and after completion of each treatment modality. At the end of the crossover study, a patient preference questionnaire was used to compare the effectiveness of the two modalities. RESULTS - Compared with the pain VAS scores before active (6.2 ± 1.0) and sham (6.4 ± 0.9) treatments, pain scores after treatment were reduced to 215 ± 0.8 and 6.3 ± 1.1, respectively with active PENS treatment, the VAS activity and sleep scores were significantly improved from 5.2 ± 1.0 and 5.8 ± 1.3 to 7.9 ± 1.0 and 8.3 ± 0.7, respectively. The VAS scores for pain, activity, and sleep were unchanged from baseline values after the sham treatments. Patients' daily oral nonopioid analgesic requirements decreased by 49 and 14{\%} after active and sham PENS treatments, respectively. The post-treatment physical and mental components of the SF-36, the BDI, and the POMS all showed a significantly greater improvement with active versus sham treatments. Active PENS treatment improved the neuropathic pain symptoms in all patients. CONCLUSIONS - PENS is a useful nonpharmacological therapeutic modality for treating diabetic neuropathic pain. In addition to decreasing extremity pain, PENS therapy improved physical activity, sense of well-being, and quality of sleep while reducing the need for oral nonopioid analgesic medication.",
author = "Hamza, {Mohamed A.} and White, {Paul F.} and Craig, {William F.} and Ghoname, {El Sayed A} and Ahmed, {Hesham E.} and Proctor, {Timothy J.} and Noe, {Carl E.} and Vakharia, {Akshay S.} and Noor Gajraj",
year = "2000",
month = "3",
language = "English (US)",
volume = "23",
pages = "365--370",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Percutaneous electrical nerve stimulation

T2 - A novel analgesic therapy for diabetic neuropathic pain

AU - Hamza, Mohamed A.

AU - White, Paul F.

AU - Craig, William F.

AU - Ghoname, El Sayed A

AU - Ahmed, Hesham E.

AU - Proctor, Timothy J.

AU - Noe, Carl E.

AU - Vakharia, Akshay S.

AU - Gajraj, Noor

PY - 2000/3

Y1 - 2000/3

N2 - OBJECTIVE - To evaluate the use of percutaneous electrical nerve stimulation (PENS) in the management of patients with painful diabetic peripheral neuropathy RESEARCH DESIGN AND METHODS - A total of 50 adult patients with type 2 diabetes and peripheral neuropathic pain of >6 months duration involving the lower extremities were randomly assigned to receive active PENS (needles with electrical stimulation at an alternating frequency of 15 and 30 Hz) and sham (needles only) treatments for 3 weeks. Each series of treatments was administered for 30 min three times a week according to a standardized protocol. After a 1-week washout period, all patients were subsequently switched to the other modality. A 10-cm visual analog scale (VAS) was used to assess pain, physical activity, and quality of sleep before each session. The changes in VAS scores and daily requirements for oral analgesic medication were determined during each 3-week treatment period. Patients completed the MOS 36-Item Short-Form Health Survey (SF-36), the Beck Depression Inventory (BDI), and the Profile of Mood States (POMS) before and after completion of each treatment modality. At the end of the crossover study, a patient preference questionnaire was used to compare the effectiveness of the two modalities. RESULTS - Compared with the pain VAS scores before active (6.2 ± 1.0) and sham (6.4 ± 0.9) treatments, pain scores after treatment were reduced to 215 ± 0.8 and 6.3 ± 1.1, respectively with active PENS treatment, the VAS activity and sleep scores were significantly improved from 5.2 ± 1.0 and 5.8 ± 1.3 to 7.9 ± 1.0 and 8.3 ± 0.7, respectively. The VAS scores for pain, activity, and sleep were unchanged from baseline values after the sham treatments. Patients' daily oral nonopioid analgesic requirements decreased by 49 and 14% after active and sham PENS treatments, respectively. The post-treatment physical and mental components of the SF-36, the BDI, and the POMS all showed a significantly greater improvement with active versus sham treatments. Active PENS treatment improved the neuropathic pain symptoms in all patients. CONCLUSIONS - PENS is a useful nonpharmacological therapeutic modality for treating diabetic neuropathic pain. In addition to decreasing extremity pain, PENS therapy improved physical activity, sense of well-being, and quality of sleep while reducing the need for oral nonopioid analgesic medication.

AB - OBJECTIVE - To evaluate the use of percutaneous electrical nerve stimulation (PENS) in the management of patients with painful diabetic peripheral neuropathy RESEARCH DESIGN AND METHODS - A total of 50 adult patients with type 2 diabetes and peripheral neuropathic pain of >6 months duration involving the lower extremities were randomly assigned to receive active PENS (needles with electrical stimulation at an alternating frequency of 15 and 30 Hz) and sham (needles only) treatments for 3 weeks. Each series of treatments was administered for 30 min three times a week according to a standardized protocol. After a 1-week washout period, all patients were subsequently switched to the other modality. A 10-cm visual analog scale (VAS) was used to assess pain, physical activity, and quality of sleep before each session. The changes in VAS scores and daily requirements for oral analgesic medication were determined during each 3-week treatment period. Patients completed the MOS 36-Item Short-Form Health Survey (SF-36), the Beck Depression Inventory (BDI), and the Profile of Mood States (POMS) before and after completion of each treatment modality. At the end of the crossover study, a patient preference questionnaire was used to compare the effectiveness of the two modalities. RESULTS - Compared with the pain VAS scores before active (6.2 ± 1.0) and sham (6.4 ± 0.9) treatments, pain scores after treatment were reduced to 215 ± 0.8 and 6.3 ± 1.1, respectively with active PENS treatment, the VAS activity and sleep scores were significantly improved from 5.2 ± 1.0 and 5.8 ± 1.3 to 7.9 ± 1.0 and 8.3 ± 0.7, respectively. The VAS scores for pain, activity, and sleep were unchanged from baseline values after the sham treatments. Patients' daily oral nonopioid analgesic requirements decreased by 49 and 14% after active and sham PENS treatments, respectively. The post-treatment physical and mental components of the SF-36, the BDI, and the POMS all showed a significantly greater improvement with active versus sham treatments. Active PENS treatment improved the neuropathic pain symptoms in all patients. CONCLUSIONS - PENS is a useful nonpharmacological therapeutic modality for treating diabetic neuropathic pain. In addition to decreasing extremity pain, PENS therapy improved physical activity, sense of well-being, and quality of sleep while reducing the need for oral nonopioid analgesic medication.

UR - http://www.scopus.com/inward/record.url?scp=0034006763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034006763&partnerID=8YFLogxK

M3 - Article

C2 - 10868867

AN - SCOPUS:0034006763

VL - 23

SP - 365

EP - 370

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -